ALVO

Alvotech

$4.88

4.05%

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

Source: Yahoo Finance
AI summary

Price & performance

1M-12.8%
3M+45.7%
YTD+2.6%
1Y-39.8%
52-week range—
Beta0.74
Full chart and returns against a benchmark

Q-Score

48/ 100

Quality against peers; 50 is the peer median.

Growth66
Risk52
Performance38
Valuation50
Profitability50
Leverage48
Sentiment48
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$586.3M+19.7%
Net income$27.9M
Net margin4.8%+52.1 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsMar 31, 2026
Filings, findings and the timeline

Valuation

ALVOIndustryP/E62.3735.25P/S2.972.74EV/EBITDA36.6716.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 11next report, after the close
EPS estimate$-0.04
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate